To Study the adjuvant effect of Netrashani Rasa and Guduchi-Triphaladi Kwatha orally with conventional Anti-Glaucoma eye drops in Primary Open Angle Glaucoma

Adjuvant Effect of Netrashani Rasa and Guduchi-Triphaladi Kwatha Orally with Conventional Antiglaucoma Eyedrop in Kaphaja Adhimantha(POAG)-An Open Label Randomized Control Trial - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/112491

Enrollment

Registered

2026-06-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H401- Open-angle glaucoma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients suffering with clinical features of Kaphaja Adhimantha(POAG). 2.Patients having complaints Delayed Dark Adaptation, Headache.

Exclusion criteria

Exclusion criteria: 1.All types of closed-angle glaucoma. 2.Primary Open-Angle Glaucoma (POAG) with advanced optic atrophy and established blindness. 3.Secondary and developmental glaucoma, including exfoliative glaucoma, pigmentary glaucoma, trauma-induced glaucoma, and inflammatory glaucoma. 4.Presence of malignancy, uncontrolled diabetes mellitus, or uncontrolled hypertension. 5.Evidence of anterior segment pathology such as conjunctivitis, keratitis, or acute uveitis. 6.End-stage glaucomatous optic neuropathy presenting with only central vision (tunnel vision). 7.Ocular hypertension with very low or moderate risk of conversion to POAG. 8.POAG associated with severe myopic degeneration, central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), or chorioretinitis. 9.POAG with coexisting optic disc anomalies such as drusen, coloboma, papillitis, papilledema, or compressive optic nerve lesions. 10.History of opaque ocular media (e.g., cataract, corneal opacity, vitreous opacities). 11.Individuals already enrolled in another ongoing medical research study

Design outcomes

Primary

Measure	Time frame
Assessment of Delayed dark adaptation assessment of Headache severity/frequencyTimepoint: 0 day, 45th day, 60th day	—

Secondary

Measure	Time frame
changes in corrected visual acuity changes in IOP from baseline changes in Automated perimetry parameters changes in OCT parameters changes in CDR from baselineTimepoint: 0 day, 60th day	—

Countries

India

Contacts

Public ContactAkriti Gupta

Patanjali Bhartiya Ayurvigyan Evum Anusandhan Sansthan Haridwar

jyotiguptania@gmail.com09997907340

Outcome results